Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 847 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR EMA Recommends Additional Extensions of Indications for Pembrolizumab October 7, 2024 March is Colon Cancer Awareness Month March 11, 2021 ESMO Welcomes Launch of Health Package Introducing EU Measures That Can... December 19, 2025 FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma August 27, 2024 Load more HOT NEWS Adolescent and Young Adult Cancer Survivors Face More Co-morbidity in Later... ScottishPower help us shine a light on air pollution and cancer Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent... Trastuzumab Deruxtecan Leads to Longer PFS and OS Compared with Chemotherapy...
